|
Zydus Lifesciences announced that its formulation manufacturing facility, 'SEZ 2', located in Pharmez, Ahmedabad, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). The inspection, which took place from 3rd to 7th July 2023, was conducted as a Pre-Approval Inspection (PAI) and it concluded with zero observations.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company reported 109.7% surge in net profit to Rs 1,086.9 crore while revenue from operations jumped 29.6% to Rs 5,139.6 crore in Q1 June 2023 over Q1 June 2022.
The scrip added 0.34% to Rs 643.45 on 18 September 2023.
|